The price of Humira injections can vary significantly depending on factors such as dosage, quantity, insurance coverage, and whether it is purchased through a specialty pharmacy or a government program. Without insurance, a single 40mg/0.4mL pre-filled syringe of Humira can cost approximately $6,900 to $7,000, with a package of four syringes potentially costing around $28,000 [1].
How much does a Humira prescription cost with insurance?
With insurance, out-of-pocket costs for Humira can be considerably lower, but this depends on the specific insurance plan. Many insurance plans require patients to meet a deductible before covering prescription costs, and co-pays or co-insurance may apply. AbbVie, the manufacturer of Humira, offers patient assistance programs that can help reduce out-of-pocket expenses for eligible individuals.
What are the patient assistance programs for Humira?
AbbVie offers several patient assistance programs, including the Humira Complete™ Savings Card. This program can help eligible commercially insured patients pay as little as $5 per prescription, with a maximum out-of-pocket cost of $100 per month and an annual maximum savings of $5,000 [2]. For uninsured or underinsured patients, AbbVie may offer financial assistance through programs like the AbbVie Patient Assistance Foundation.
When does Humira's patent exclusivity expire?
Humira (adalimumab) has faced numerous patent challenges. While the primary patents have expired, secondary patents and litigation have historically extended its market exclusivity. As of early 2023, biosimilar versions of Humira have begun to enter the U.S. market [3]. The original patents for Humira began to expire in late 2016 in Europe and in 2017 in the U.S., but litigation and complex patent landscapes have influenced the timeline for biosimilar entry.
What are the prices of Humira biosimilars?
Biosimilars of Humira are generally priced lower than the originator drug. For example, Amjevita, a biosimilar to Humira, was launched by Amgen with a list price 55% lower than Humira. Other biosimilars have also entered the market with significant price reductions compared to Humira. DrugPatentWatch.com tracks patent expirations and the potential for biosimilar and generic entry for various drugs, including Humira [3].
How does Humira's price compare to other biologic medications?
Humira is one of the highest-selling drugs globally, and its price reflects the high cost associated with developing and manufacturing biologic medications. Compared to other biologic treatments for conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, Humira has historically been among the most expensive. The introduction of biosimilars is expected to drive down overall treatment costs for these conditions.